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Abstract
Background: Transcutaneous neurostimulation (TNS) at extracephalic sites is a well known treatment of pain.
Thanks to recent technical progress, the Cefaly
® device now also allows supraorbital TNS. During observational
clinical studies, several patients reported decreased vigilance or even sleepiness during a session of supraorbital
TNS. We decided therefore to explore in more detail the potential sedative effect of supraorbital TNS, using
standardized psychophysical tests in healthy volunteers.
Methods: We performed a double-blind cross-over sham-controlled study on 30 healthy subjects. They underwent
a series of 4 vigilance tests (Psychomotor Vigilance Task, Critical Flicker Fusion Frequency, Fatigue Visual Numeric
Scale, d2 test). Each subject was tested under 4 different experimental conditions: without the neurostimulation
device, with sham supraorbital TNS, with low frequency supraorbital TNS and with high frequency supraorbital TNS.
Results: As judged by the results of three tests (Psychomotor Vigilance Task, Critical Flicker Fusion Frequency,
Fatigue Visual Numeric Scale) there was a statistically significant (p < 0.001) decrease in vigilance and attention
during high frequency TNS, while there were no changes during the other experimental conditions. Similarly,
performance on the d2 test was impaired during high frequency TNS, but this change was not statistically
significant.
Conclusion: Supraorbital high frequency TNS applied with the Cefaly
® device decreases vigilance in healthy
volunteers. Additional studies are needed to determine the duration of this effect, the underlying mechanisms and
the possible relation with the stimulation parameters. Meanwhile, this effect opens interesting perspectives for the
treatment of hyperarousal states and, possibly, insomnia.
Background
Neurostimulation is a therapeutic method where action
potentials are elicited by depolarizing nerve fibres with
electrical impulses produced by a current generator
device generally called neurostimulator. This method is
used percutaneously with implantable neurostimulators
and electrodes positioned over the spinal cord or per-
ipheral nerves, or transcutaneously via superficial skin
electrodes and external neurostimulators.
Percutaneous neurostimulation (PNS) of the spinal
cord has been developed in the last decade for the man-
agement of intractable pain [1,2], but also for the treat-
ment of several neurological disorders such as spasticity
[3], parkinsonian tremor [4] or epilepsy [5], More
recently, PNS has been explored for the treatment of
intractable headaches [6-11].
Transcutaneous neurostimulation (TNS) is a classical
technique which has demonstrated its efficacy in the treat-
ment of pain [12,13] and is nowadays largely in use in pain
clinics and physical therapy centres. It has the advantage
of being non-invasive, safe and almost devoid of adverse
effects contrary to PNS which needs a surgical interven-
tion to implant the electrodes and the neurostimulator.
TNS at cephalic sites has been technically difficult and
usually rather painful. STX-Med company has recently
developed a headset for TNS of supratrochlear and
supraorbital nerves, both branches of the ophthalmic
division of the trigeminal nerve (V1), making the techni-
que comfortable and easy to use [14]. Consequently, the
utility of TNS in the treatment and prevention of head-
aches and migraine has been investigated [15] and several
clinical trials are underway. Subjects enrolled in those
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tended to affect vigilance and decrease attention with a
tendency to fall asleep during the stimulation.
Cephalic electrical stimulation has been used many
years ago to induce sleep or decrease anxiety. The
method known as “Cranial Electrotherapy Stimulation
(CES)”, also called transcranial or transcerebral electrosti-
mulation differs from TNS in that its objective is to gen-
erate different types of electrical currents through the
head and not to specifically stimulate cranial nerves like
TNS. For this purpose, CES uses generally an anterior
frontal or a jaw electrode and a posterior electrode placed
over the mastoid process [16,17]. CES was reported to
have some effects on anxiety, depression and insomnia
[18-20].
Given the anecdotal reports by patients of TNS-
induced sedative effects, not hitherto reported in the lit-
erature, and the reported mental effects of CES, we
decided to explore the effect on vigilance of supraorbital
TNS with the headset developed by STX-Med in a dou-
ble blind cross-over study.
Methods
We performed a double-blind crossover sham-controlled
study of 30 subjects to assess the effect on vigilance of
different protocols of supra-orbital TNS. Each subject
was tested in 4 different experimental conditions: without
neurostimulation device (blank control: BC), with a sham
neurostimulation (Sham control: SC), with a low fre-
quency neurostimulation (LFN) and with a high fre-
quency neurostimulation (HFN). The study protocol was
approved by the local ethics committee (CE B200-2010-
074-2010-05-03).
Subjects
We included 30 healthy subjects: 15 men and 15 women
ranging in age from 19 to 29 years (mean age = 23,9 +/-
2.4).
To be eligible, subjects had to be right-handed, drink
no more than 1 cup of tea or coffee per day and no
more than 2 glasses of alcohol per week. Exclusion cri-
teria were a history of serious surgical, medical or psy-
chiatric disease, smoking, and drug intake. Informed
consent was obtained for all subjects prior to the study.
Neurostimulation
Supra-orbital neurostimulation was delivered with an
external self adhesive electrode placed on the forehead
(see Figure 1). The bipolar electrode is designed in order
to cover the supratrochlear and supraorbital nerves bilat-
erally. Its dimensions are 30 mm × 94 mm.
The neurostimulator was a Cefaly
® device (STX-Med,
Liège, Belgium). It is a constant current generator for a
maximum skin impedance of 2.2 KΩ. It generates
biphasic rectangular impulses with an electrical mean
equal to zero. The impulses have the following para-
meters: impulse width 250 μS, maximum intensity 14
mA. Low frequency neurostimulation (LFN) was deliv-
ered at a frequency of 2.5 Hz, high frequency neurosti-
mulation (HFN) at 120 Hz. The neurostimulation lasted
20 minutes. For both LFN and HFN, the intensity
reached was above perception threshold, so that all sub-
jects experienced paresthesias and tingling under the sti-
mulation electrodes. For sham neurostimulation (SC) we
used a Cefaly
® device with a low current intensity of
1 mA that was below the perception threshold and pro-
duced no sensation detectable by the subjects.
Psychophysical measures
Four psychophysical tests were selected to detect seda-
tive effects.
1) The Psychomotor Vigilance Task (PVT) was devel-
oped [21] to measure performance during mental fatigue.
It is regarded as the gold standard for sleepiness.
We used the PEBL [22] implementation of the PVT
(PPVT). Briefly, the subject sits in front of a black
Figure 1 The stimulation electrode placed on the forehead
covers the supratrochlear and supraorbital nerves.
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Page 2 of 7computer screen. As soon as a red dot appears, the sub-
ject is supposed to hit the space bar of the computer key-
board. The reaction time is recorded in milliseconds. In
total 12 reaction times measures are measured for each
PVT test, separated randomly by intervals of 2 to 12 sec-
onds. The results are expressed as the mean value of the
12 measures.
2) The Critical Flicker Fusion Frequency ( C F F F )t e s ti s
defined as “the highest or lowest temporal frequency, at a
given percentage modulation, that can be resolved” [23],
i.e. the frequency at which the subject is able to distinguish
a flashing from a steady light. The CFFF decreases with
fatigue. A portable device powered with a 9 V battery and
equipped with a blue LED was used to vary flicker fre-
quency by 0.5 Hz steps. The device starts with a steady
light and the flicker frequency is decreased until the sub-
ject reports that the light is flashing. This frequency is
recorded as the CFFF for that experiment.
3) The d2 test for attention and concentration [24]
allows to assess visual attention and the ability to concen-
trate on a task. It consists of 14 lines of a combination of
the letters “d” and “p” with one to four dashes placed
above and/or below the letter. The objective is to mark
all “d” with two dashes within 20 seconds for each line.
Three scores are evaluated: GZ ("Gesamtzahl der bearbei-
teten Zeichen”) is the total number of letters marked; KL
("Konzentrationsleistungswert”) is the number of correct
letters marked minus the number of non correct letters;
and F% ("Fehlerprozentwert”) representing the percen-
tage of errors compared to the number of characters
marked (GZ). As this test can be biased by a learning
effect, it is only presented once during the session with-
out recording of a baseline.
4) For the subjective evaluation of fatigue we used the
Fatigue Visual Numeric Scale (FVNS - Stanford Patient
Education Research Centre [25]. This is a visual analo-
gue scale where the subject scores fatigue from 0 (not
tired at all) to 10 (very tired).
Procedures
T w og r o u p so f8s u b j e c t sa n dt w og r o u p so f6g r o u p s
performed the experiments as depicted in Table 1. The
s e s s i o n sw e r es e p a r a t e db ya tl e a s t6h o u r sa st oe n s u r e
there was no remaining effect of the stimulation.
At the first session, each subject of the group is ran-
domly assigned to one of the 4 experimental conditions:
￿ LFN, where the subjects get a Low Frequency
Neurostimulation
￿ HFN, where the subjects get a High Frequency
Neurostimulation
￿ SC, where the subjects get a sham neurostimula-
tion (Sham Control)
￿ BC, where the subjects do not have a device (Blank
Control)
Two subjects are assigned to each condition. In the
subsequent sessions, the same subjects are re-assigned
to another condition in order for each of them to have
been through each condition after the 4 sessions.
The subjects are sitting comfortably in a chair in front
of a wall to avoid any distraction. Once the session has
started, each subject fills in the FVNS and performs the
PPVT test where after the CFFF is determined. After
these baseline tests, the neurostimulation is started for all
subjects assigned to conditions LFN, HFN and SC while
no neurostimulation is applied for the subjects assigned
to condition BC. After 10 minutes of stimulation for
LFN, HFN and SC or a 10-minute waiting time for BC,
the subjects perform the d2 test that lasts 280 s. There-
after they score FVNS once more, redo the PPVT test
and finally have the CFFF measured again. The psycho-
physical tests are thus studied in the same sequence
under every experimental condition.
This means in practice that we have a set of results for
FVNS, PPVT and CFFF as measured before the applica-
tion of the neurostimulator. A second set of results is
obtained while the neurostimulator is applied since ± 15
minutes. The results can therefore also be expressed as a
percentage of the measurement during the neurostimula-
tion compared to the baseline value recorded before the
neurostimulation.
Statistical Analysis
We compared the results of the psychophysical tests for
each of the 4 experimental conditions: LFN, HFN, SC
and BC. For FVNS, PPVT and CFFF we used the varia-
tion in percentage between pre- and perstimulation
values to verify the effects of the 4 conditions. Since the
Table 1 Schedule of the experiments for each group
First
Experiment
Second
Experiment
Third
Experiment
Fourth
Experiment
Group I Tuesday 8 AM Tuesday 2 PM Thursday 8 AM Thursday 2 PM
Group II Tuesday 9 AM Tuesday 3 PM Thursday 9 AM Thursday 3 PM
Group III Tuesday 10 AM Tuesday 4 PM Thursday 10 AM Thursday 4 PM
Group IV Tuesday 11 AM Tuesday 5 PM Thursday 11 AM Thursday 5 PM
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Page 3 of 7results did not have a Gaussian distribution, we used the
Wilcoxon test to measure the significance of the varia-
tion observed.
For the d2 test, we compared GZ, KL and the F%
between the 4 conditions (as there was no control values
to compare with). We have used the Mann-Whitney test
to verify the significance of the differences observed.
Results
PPVT Test
The mean reaction times (RT) for the PPVT (N = 30)
before the session was 339 ms+176 for LFN, 304 ms +3 7
for HFN, 294 ms +4 4f o rS Ca n d3 0 6m s+4 6f o rB C .
Reaction time increased during HFN, while it was stable
for the LFN, SC and BC conditions (Figure 2).
As explained in the methods section, for FVNS, PPVT
and CFFF the statistical analysis was performed on the
ratio (in percentage) between the mean value during
and before the experimental condition for each subject.
The mean percentage increase in RT is significant only
during the HFN condition (p = 0.0002).
CFFF Test
The mean values for CFFF (N = 30) before the session was
38.2 Hz + 2.5 for LFN, 39.7 Hz + 2.7 for HFN, 39.9 Hz +
3.3 for SC and 38.2 Hz + 2.2 for BC. During HFN there
was a significant decrease of CFFF (p < 0.0001) while
CFFF was significantly increased during LFN (Figure 3).
d2 Test
Table 2 shows the results for the d2 test. Mean values of
GZ, KL and F% are given during each experimental con-
dition the. Numerically the total number of letters
marked (GZ) and the number of correct letters marked
(KL) were the lowest in the HFN condition, while the
percentage of errors was the highest, but this difference
was not statistically significant.
Fatigue Visual Numeric Scale
The FVNS fatigue score tended to increase during all
four conditions. However, the statistical analysis for the
averaged individual changes showed that the increase
was significant only during HFN (Figure 4).
Discussion
Taken together our results suggest that supraorbital neu-
rostimulation using the Cefaly
® device decreases arousal
and induces fatigue. This cannot be considered at this
stage as a hypnotic effect in the sense of inducing sleep
and decreasing sleep latency but rather as a sedative effect
in terms of a reduction of alertness and vigilance. Interest-
ingly, this is only the case with high (120 Hz-HFN) and
not with low frequency (2.5 Hz-LFN) stimulation. LFN
even has an opposite effect in one psychophysical test, the
critical flicker fusion frequency. Below we will examine
these results in more detail and speculate on possible
mechanisms.
The Psychomotor Vigilance Task measures the reac-
tion time (RT) and is considered as the gold standard for
measuring sleepiness [21]. That it is readily reproducible
is demonstrated by the fact that during the blank condi-
tion (BC) the change compared to baseline was less than
1.5%. Sham (SC) and LFN induced non significant
increases in RT of respectively 8.9 ms and 8.6 ms. By
contrast, HFN increased RT by an average of 36.7 ms, i.e.
by more than 10%. Critical flicker fusion frequency is
known to decrease with fatigue. While unchanged during
SC and minimally increased during BC (+ 0.9 Hz), it
increased during LFN (+ 1.9 Hz) possibly suggesting a
mild increase in vigilance. Again HFN contrasted with all
other conditions by a marked decrease (-4.6 Hz) in CFFF,
indicating a decrease in arousal. This result is concordant
with that of the subjective fatigue rating on the Fatigue
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Figure 2 Mean PPVT reaction time change during the
experimental conditions expressed as a percentage of the
baseline value (*** = p < 0.001) (mean+/-SEM).
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Figure 3 Mean CFFF change during the experimental
conditions expressed as a percentage of the baseline value (**
= p < 0.01; *** = p < 0.001) (mean+/-SEM).
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Page 4 of 7Visual Numerical Scale (FVNS). The subjects rated their
fatigue higher during all experimental conditions than at
baseline, which was not significant and might be related
to the mental strain due to the recordings or to a learning
effect in using the numerical scale. However, the increase
of the FVNS score during HFN was three times greater
(+ 72.1%). The d2 test for attention and concentration
was in our study the only one for which the HFN condi-
tion induced no significant effect. Nevertheless the
numerical changes during HFN are in line with the other
results as they show a lower number of total letters
marked and of correct letters marked as well as a higher
number of errors. The lack of significance could have at
least two explanations. First, the d2 test was administered
at an earlier time point (between 10 and 15 minutes) dur-
ing the experimental condition compared to the other
tests (from 15 minutes onwards). The duration of HFN
might thus not have been long enough to produce signifi-
cant d2 test changes. Second, this test was performed
only once to avoid a learning effect and the pre- and per-
condition comparison had therefore to be replaced by a
comparison between conditions, hence weakening the
sensitivity of the test to detect a change.
To the best of our knowledge, this is the first time that
the effect of transcutaneous neurostimulation on arousal
and fatigue was studied in humans and there are no simi-
lar studies available in animals. The neurobiological
mechanisms through which HFN induces sedation remain
therefore speculative. Some insight can nonetheless be
gained from the studies of transcutaneous neurostimula-
tion in Alzheimer’s patients and from those in experimen-
tal animals of the central nervous system consequences of
electroacupuncture. A Dutch group reported in a series of
publications that transcutaneous electrostimulation was
able to improve memory, alertness [26,27] and rest-activity
rhythm [28] in Alzheimer’s disease. This effect was attrib-
uted to activation of the hippocampus and the suprachias-
matic nucleus both by direct spinal cord afferents [29] and
via the dorsal raphe nucleus and locus coeruleus [30,31].
Although vigilance was not specifically measured in these
studies, the observed cognitive and behavioural effects
would suggest increased arousal and vigilance rather than
sedation like in our study. This opposite effects can prob-
ably be explained by the different stimulation protocols.
First, Alzheimer patients received transcutaneous neuro-
stimulation over paravertebral back muscles daily during 6
[26] or 3 hours [27,28] for 6 weeks while we used a single
20-minute session of supraorbital neurostimulation. In a
more recent randomized sham-controlled pilot trial of
right median nerve stimulation, Scherder et al [32] found
no significant effect on memory in Alzheimer’s disease
and the same group reported that cranial electrostimula-
tion had no effect on rest-activity rhythm neither at low
frequency [33] nor at high frequency [34]. More interest-
ingly, we found a hypnotic effect with high frequency (120
Hz) stimulation, whereas the beneficial effects in Alzhei-
mer’s disease were obtained with burst of stimuli (9 pulses
at 160 Hz) delivered at a low frequency of 2 Hz, a fre-
quency that in our study concordantly increased critical
flicker fusion frequency. One may assume that high and
low frequency stimulations can have different effects on
central nervous system structures and thus on arousal, but
this remains to be proven in an adequate study.
Transcranial direct current stimulation (tDCS) is able to
modulate cortical activity under certain conditions and in
certain brain areas. It is extremely unlikely, however, that
the supraorbital TNS used in this study influences directly
the underlying brain structures, i.e. the frontal lobes, for at
least two reasons. First, The small electrode surface (7
cm²) and distance between the two electrodes (5 mm)
restrict the skin surface affected by the current as well as
current penetration into deeper structures. Second, the
TNS applied current is composed of biphasic rectangular
impulses with an electrical mean equal to zero, while
tDCS uses a direct current. The current characteristics
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Figure 4 Mean change in FNVS score during the experimental
conditions expressed as a percentage of the baseline value
(*** = p < 0.001) (mean+/-SEM).
Table 2 d2 results
N = 30 LFN HFN SC BC
Mean value of GZ 560 ± 77 544 ± 80 587 ± 57 562 ± 70
Mean value of KL 215 ± 40 214 ± 50 229 ± 42 217 ± 43
Mean value of F% 6.95% ± 6.81 8.37% ± 8.38 6.02% ± 5.98 6.72% ± 6.16
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Page 5 of 7and the mechanisms of action are thus different between
trigeminal TNS and tDCS. Moreover, in a recent study
[35], weak transcranial electrical DC or AC currents over
the prefrontal cortex had no effect on mood or EEG in
healthy subjects. Interestingly, sleepiness was reported
rarely both in the active (0.11%) and sham stimulation
groups (0.08%).
Experimental studies on the mode of action of electroa-
cupuncture in pain are relevant to this discussion
because many of the central nervous system structures
activated by electroacupuncture like the monoaminergic
brain stem nuclei, the hypothalamic arcuate nucleus or
the periaqueductal gray matter also play a role in vigi-
lance states (36,37,38,39). A simple straightforward expla-
nation for the sedative effects found in our study would
be an effect of the transcutaneous stimulation on monoa-
minergic brain stem nuclei such as locus coeruleus that
receives direct spinal input [40]. The locus coeruleus is
also thought to mediate the anti-epileptic effect of high
frequency transcutaneous stimulation of the ophthalmic
nerve [41]. However, in animals high frequency electroa-
cupuncture was found to increase neuronal activity in
brain stem nuclei [36], in particular in dorsal raphe
nuclei [37]. Increased activity of these nuclei that belong
to the ascending activating reticular system would be
associated with increased rather than decreased arousal
and vigilance. Electroacupuncture over peripheral nerves
also activates the hypothalamic arcuate nucleus in ani-
mals [39]. The arcuate nucleus plays a pivotal role in
electroacupuncture-induced cardiovascular inhibition
[39], but also in vigilance states via its reciprocal connec-
tions with orexin-containing lateral hypothalamic neu-
rons and the ventrolateral periaqueductal gray matter
(38,42). A change in activity levels of the orexin-arcuate-
periaqueductal gray matter circuit could occur during
supraorbital neurostimulation and might explain the
decrease in vigilance. Future studies of supraorbital neu-
rostimulation coupled to functional cerebral imaging stu-
dies could verify this hypothesis. Further studies are also
needed to verify whether the sedative effects of HFN as
evidenced here by psychophysical tests have electroence-
phalographic correlates and if they are associated with
hypnotic effects such as sleep latency reduction.
Conclusion
To sum up, we have shown in healthy volunteers that
supraorbital high frequency neurostimulation applied
with the Cefaly
® device modifies concordantly several
psychophysical tests in a way that is compatible with
decreased vigilance and arousal, while sham stimulation
has no effect and low frequency neurostimulation, if
anything, tends to increase arousal. The precise mechan-
isms of action of HFN on the CNS arousal systems are
not known and warrant further studies. Meanwhile
supraorbital HFN with the Cefaly
® device opens inter-
esting perspectives for an adverse effect-free treatment
of hyperarousal states, and possibly sleep disorders.
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